Current Report Filing (8-k)
09 October 2021 - 8:31AM
Edgar (US Regulatory)
0001729944
false
0001729944
2021-10-04
2021-10-04
0001729944
IMAC:CommonStockParValue0.001PerShareMember
2021-10-04
2021-10-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): October 4, 2021
IMAC
Holdings, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38797
|
|
83-0784691
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
1605
Westgate Circle, Brentwood, Tennessee
|
|
37027
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code: (844) 266-4622
Not
applicable
(Former
Name or Former Address, If Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class
|
|
Trading
Symbol
|
|
Name
of Each Exchange on Which Registered
|
Common
Stock, par value $0.001 per share
|
|
IMAC
|
|
NASDAQ
Capital Market
|
Warrants
to Purchase Common Stock
|
|
IMACW
|
|
NASDAQ
Capital Market
|
☐
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2)
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
CURRENT
REPORT ON FORM 8-K
IMAC
Holdings, Inc. (the “Company”)
October
4, 2021
Item
2.01.
|
Completion
of Acquisition or Disposition of Assets.
|
On
October 4, 2021, pursuant to a Stock Purchase Agreement, dated as of October 4, 2021, the Company acquired from F. Allen Johnston, M.D.
all of the outstanding common stock of Louisiana Orthopaedic & Sports Rehab Institute for $1.6 million, consisting of $1.2 million
in shares of the Company’s common stock issued at closing and $400,000 in cash, payable in four equal quarterly installments during
the 12 months following the closing, plus up to an additional $200,000 based on an increase in Louisiana Orthopaedic’s total new
patients during the first nine months of 2022 compared to the prior nine-month period. The purchase price was determined as a result
of arm’s-length negotiations between the parties.
Separately,
on October 4, 2021, pursuant to an Asset Purchase Agreement, dated as of October 1, 2021, the Company (through its wholly-owned subsidiary,
IMAC Medical of Louisiana, a medical corporation) purchased substantially all of the professional assets and certain other assets related
to the operation of a medical practice conducted by F. Allen Johnston MD, PC, a Louisiana professional corporation, and assumed certain
of the liabilities of the medical practice, for $800,000 in cash. The purchase price was determined as a result of arm’s-length
negotiations between the parties.
Louisiana
Orthopaedic is a practice management company serving the Baton Rouge community since 1988. The company offers orthopaedic and sports
medicine services and treats acute sports, accident and work-related injuries among others, helping patients procure the appropriate
treatment and medicine easily. Its founder, Dr. F. Allen Johnston, an orthopedic surgeon, will continue to see patients at Louisiana
Orthopaedic’s medical center (conducted through his medical practice) and will join the Company as a Medical Director.
The
cash portion of the acquisitions were funded by cash on hand from operations and prior equity financings.
Neither
Louisiana Orthopaedic nor F. Allen Johnston MD, PC had any material relationship or association with the Company. The acquisitions will
be accounted for under the purchase method of accounting.
There
are presently no significant changes anticipated in the business or product lines of either the Company or Louisiana Orthopaedic or F.
Allen Johnston MD, PC.
The
foregoing summary description of the Stock Purchase Agreement and Asset Purchase Agreement set forth herein is qualified by reference
to the full text of both the Stock Purchase Agreement and Asset Purchase Agreement, a copy of each of which is attached hereto as Exhibit
2.1 and 2.2, respectively, and each of which is incorporated herein in its entirety.
The
Company announced the closing of the acquisition in a press release issued on October 4, 2021, a copy of which is attached hereto as
Exhibit 99.1 and is incorporated in its entirety by reference.
Item
3.02.
|
Unregistered
Shares of Equity Securities.
|
The
information set forth above in Item 2.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 3.02.
The shares of the Company’s common stock issued under the terms of the above-described Stock Purchase Agreement were not registered
under the Securities Act of 1933, as amended, in reliance upon the exemption from registration provided by Section 4(a)(2) thereof, which
exempts transactions by an issuer not involving any public offering.
Item
9.01. Financial Statements and Exhibits.
(a)
Financial Statements of Businesses Acquired. In accordance with Item 9.01(a), the financial statements of Louisiana Orthopaedic
& Sports Rehab Institute are not “significant” and therefore not required to be filed pursuant to Item 3.05(b) of Regulation
S-X.
(b)
Pro Forma Financial Information. In accordance with Item 9.01(b), the pro forma financial information is not “significant”
and therefore not required to be filed pursuant to Article 11 of Regulation S-X.
(d)
Exhibits.
Exhibit
Number
|
|
Description
|
|
|
|
2.1
|
|
Stock Purchase Agreement, dated as of October 4, 2021, by IMAC Holdings, Inc. and F. Allen Johnston, M.D.*
|
|
|
|
2.2
|
|
Asset Purchase Agreement, dated as of October 1, 2021, among IMAC Medical of Louisiana, a Medical Corporation, F. Allen Johnston, M.D. and F. Allen Johnston MD, PC.*
|
|
|
|
99.1
|
|
Press Release issued by IMAC Holdings, Inc. on October 4, 2021.
|
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
*Certain
of the schedules (and similar attachments) to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5) of Regulation
S-K under the Securities Act of 1933, as amended, because they do not contain information material to an investment or voting decision
and that information is not otherwise disclosed in the Exhibit or the disclosure document. The Registrant hereby agrees to furnish a
copy of all omitted schedules (or similar attachments) to the SEC upon its request.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
IMAC HOLDINGS, INC.
|
Date:
October 8, 2021
|
|
|
|
|
|
|
By:
|
/s/
Jeffrey S. Ervin
|
|
|
Jeffrey
S. Ervin, Chief Executive Officer
|
IMAC (NASDAQ:IMAC)
Historical Stock Chart
From Apr 2024 to May 2024
IMAC (NASDAQ:IMAC)
Historical Stock Chart
From May 2023 to May 2024